Cypress Asset Management Inc. TX decreased its stake in Allergan PLC. (NYSE:AGN) by 7.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,261 shares of the company’s stock after selling 100 shares during the period. Cypress Asset Management Inc. TX’s holdings in Allergan PLC. were worth $301,000 as of its most recent filing with the SEC.
Other large investors also recently made changes to their positions in the company. Veritas Asset Management LLP bought a new stake in shares of Allergan PLC. during the first quarter valued at approximately $761,339,000. Iridian Asset Management LLC CT raised its stake in shares of Allergan PLC. by 141.3% in the first quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock valued at $306,733,000 after buying an additional 751,848 shares in the last quarter. First Manhattan Co. raised its position in Allergan PLC. by 193.3% in the first quarter. First Manhattan Co. now owns 497,793 shares of the company’s stock worth $114,646,000 after buying an additional 328,062 shares in the last quarter. Schroder Investment Management Group raised its position in Allergan PLC. by 133.3% in the first quarter. Schroder Investment Management Group now owns 417,948 shares of the company’s stock worth $100,225,000 after buying an additional 238,796 shares in the last quarter. Finally, Swiss National Bank raised its position in Allergan PLC. by 20.5% in the first quarter. Swiss National Bank now owns 1,329,086 shares of the company’s stock worth $317,545,000 after buying an additional 226,200 shares in the last quarter. Hedge funds and other institutional investors own 84.77% of the company’s stock.
Allergan PLC. (AGN) opened at 242.65 on Monday. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The company’s 50 day moving average is $245.21 and its 200 day moving average is $237.12. The stock has a market cap of $81.50 billion, a P/E ratio of 7.56 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.35 EPS. Equities analysts predict that Allergan PLC. will post $16.10 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be issued a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 1.15%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s payout ratio is presently 9.95%.
WARNING: This piece was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/08/07/cypress-asset-management-inc-tx-reduces-position-in-allergan-plc-agn-updated-updated.html.
A number of research analysts have commented on AGN shares. Royal Bank Of Canada set a $279.00 price objective on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Wednesday, April 12th. Citigroup Inc. restated a “focus list” rating and issued a $261.27 price objective (up from $184.50) on shares of Allergan PLC. in a research note on Friday, April 21st. Goldman Sachs Group, Inc. (The) lowered shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target on the stock. in a research note on Wednesday, May 10th. UBS AG reiterated a “buy” rating and set a $275.00 price target on shares of Allergan PLC. in a research note on Monday, May 15th. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. Seven equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $274.14.
In other news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.36% of the company’s stock.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.
